Published in Blood on November 01, 1995
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69
The post-transplant lymphoproliferative disorder-a literature review. Pediatr Nephrol (2004) 1.92
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood (2006) 1.75
Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol (2008) 1.56
Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease. J Clin Microbiol (2002) 1.08
Lung transplantation. Part II. Postoperative management and results. West J Med (1997) 1.06
Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(★). Am J Transplant (2011) 1.04
Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. Transplantation (2008) 0.95
Epstein-Barr virus-associated Hodgkin's disease following renal transplantation. Korean J Intern Med (2006) 0.92
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep (2013) 0.89
Monitoring and managing viral infections in pediatric renal transplant recipients. Pediatr Nephrol (2011) 0.86
Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder. Pediatr Transplant (2012) 0.81
Epstein-Barr virus infection in transplant recipients: Summary of a workshop on surveillance, prevention and treatment. Can J Infect Dis (2002) 0.80
Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer (2009) 0.78
Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients. Transplant Proc (1997) 0.75
The mother lode of liver transplantation, with particular reference to our new journal. Liver Transpl Surg (1998) 0.75
Pan-hypopituitarism and diabetes insipidus after a heart transplant. J R Soc Med (2001) 0.75
Lowered Immune Cell Function in Liver Recipients Recovered From Posttransplant Lymphoproliferative Disease Who Developed Graft Tolerance. Transplant Direct (2016) 0.75
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol (1999) 17.43
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med (1998) 5.74
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med (1990) 3.88
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. J Clin Oncol (1990) 3.14
Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol (2001) 2.47
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol (2008) 2.23
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (1990) 2.13
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol (1994) 1.76
BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood (1996) 1.69
An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry (1995) 1.67
CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J Immunol (1993) 1.63
Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation (2001) 1.62
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol (1996) 1.52
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
Endocardial infiltrates in the transplanted heart: clinical significance emerging from the analysis of 5026 endomyocardial biopsy specimens. J Heart Lung Transplant (1993) 1.52
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial. J Clin Oncol (1998) 1.51
Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol (1998) 1.48
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A (1989) 1.47
Simultaneous intracoronary ultrasound and Doppler flow studies distinguish flow-mediated from receptor-mediated endothelial responses. Catheter Cardiovasc Interv (1999) 1.46
Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am (1997) 1.45
Breath pentane is a marker of acute cardiac allograft rejection. J Heart Lung Transplant (1994) 1.43
Cytomegalovirus infections in heart transplant recipients: relationship to immunosuppression. J Heart Lung Transplant (1992) 1.41
Discordant epicardial and microvascular endothelial responses in heart transplant recipients early after transplantation. J Heart Lung Transplant (1998) 1.39
Delphi-panel analysis of appropriateness of high-dose chemotherapy and blood cell or bone marrow autotransplants in diffuse large-cell lymphoma. Leuk Lymphoma (1998) 1.39
The human T-cell leukemia-lymphoma virus in the southeastern United States. JAMA (1983) 1.34
Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry (1997) 1.28
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med (1979) 1.28
Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices. Cardiac Transplant Research Database (CTRD) Group. J Heart Lung Transplant (1999) 1.26
Oestrogen receptors in human malignant melanoma. Lancet (1976) 1.26
Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res (1983) 1.25
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med (1983) 1.23
The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med (1988) 1.21
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol (1989) 1.19
Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol (2005) 1.17
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol (1993) 1.16
Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol (1989) 1.15
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol (1993) 1.14
Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. Am J Med (1979) 1.13
Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer (1978) 1.13
Predictors of quality of life in patients with advanced heart failure awaiting transplantation. J Heart Lung Transplant (1995) 1.13
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol (1998) 1.12
Characterization of the lymphocyte surface receptors for Con A and PHA. J Immunol (1975) 1.12
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Cancer Treat Rep (1977) 1.12
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol (1991) 1.11
Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol (2001) 1.11
Lymphocytes in patients with variable immunodeficiency and panhypogammaglobulinemia. Evaluation of B and T cell surface markers and a proposed classification. J Clin Invest (1974) 1.11
Production and characterization of a monoclonal antibody that binds Reed-Sternberg cells. J Immunol (1985) 1.10
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Ann Intern Med (1980) 1.10
Flow cytometric detection of HLA-specific antibodies as a predictor of heart allograft rejection. Transplantation (2000) 1.09
CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity. J Immunol (1994) 1.09
Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med (1994) 1.07
The human T-cell leukemia/lymphoma virus, lymphoma, lytic bone lesions, and hypercalcemia. Ann Intern Med (1983) 1.05
The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. Blood (2001) 1.05
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol (1989) 1.04
Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures. J Immunol (1983) 1.03
An outbreak of varicella-zoster virus infection among cancer patients. Ann Intern Med (1980) 1.03
The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 cases. J Clin Invest (1984) 1.03
Cardiac transplant outcome of patients supported on left ventricular assist device vs. intravenous inotropic therapy. J Heart Lung Transplant (2001) 1.01
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol (2013) 1.01
In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol (1988) 1.01
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med (1977) 1.01
Induction of human monocyte IL-1 mRNA and secretion during anti-CD3 mitogenesis requires two distinct T cell-derived signals. J Immunol (1991) 1.00
Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma. J Clin Microbiol (1978) 1.00
Biochemical and structural properties of a Hodgkin's disease-related membrane protein. J Immunol (1988) 0.99
Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol (1993) 0.98
Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy. J Clin Oncol (1989) 0.98
A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. Biol Psychiatry (1999) 0.98
Lymphoma classification--the gap between biology and clinical management is closing. Blood (1996) 0.98
Autologous bone marrow transplantation using unfractionated cells cryopreserved in dimethylsulfoxide and hydroxyethyl starch without controlled-rate freezing. Blood (1987) 0.97
Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. Biochemistry (1992) 0.96
An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull (1996) 0.96
Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin's lymphoma. Chest (1999) 0.96
Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol (1987) 0.96
Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant (1999) 0.96
Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. Cancer Res (1988) 0.95
Cardiovascular management of a potential heart donor: a statement from the Transplantation Committee of the American College of Cardiology. Crit Care Med (1996) 0.94
Immunologic phenotypes of diffuse, aggressive, non-Hodgkin's lymphomas. Correlation with clinical features. Cancer (1984) 0.94
Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study. Schizophr Res (1994) 0.94
Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial. Surg Clin North Am (1981) 0.93
A short echo 1H spectroscopy and volumetric MRI study of the corpus striatum in patients with obsessive-compulsive disorder and comparison subjects. Am J Psychiatry (1998) 0.93
Staging of non-Hodgkin's lymphoma. Semin Oncol (1980) 0.93
Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol (1989) 0.92
A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: influence on survival. Surgery (1981) 0.91
Increased incidence and mortality associated with skin cancers after cardiac transplant. Am J Transplant (2011) 0.91
The impact of Hodgkin's disease on the immune system. Semin Oncol (1990) 0.90
A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. J Clin Oncol (1989) 0.90
Inhibition of a specific DNA repair system and nitrosourea cytotoxicity in resistant human cancer cells. Cancer Commun (1989) 0.90
Diversity of immunological phenotypes of lymphoblastic lymphoma. Cancer Res (1983) 0.90
Immunology and cellular biology of Hodgkin's disease. Hematol Oncol Clin North Am (1989) 0.89
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. Ann Oncol (2008) 0.89
Impact of rifampin on serum amiodarone concentrations in a patient with congenital heart disease. Pharmacotherapy (1999) 0.88
Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma (2005) 0.88
Chemotherapy of ovarian cancer. Surg Clin North Am (1978) 0.88
Successful treatment of heart transplant rejection with photopheresis. Transplantation (1992) 0.88